NCT03863860 2025-07-03
A Trial of Maintenance Treatment With Fluzoparib Versus Placebo in Relapsed Ovarian Cancer Patients
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Completed
Clinical Trials
7 trialsNCT04517357 2025-02-24
A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer Patients
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Completed
NCT04718740 2023-08-14
A Drug-drug Interaction Study Of Fluzoparib (SHR3162) on Patients With Recurrent Ovarian Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Completed
NCT03075462 2022-07-01
A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Completed
NCT03509636 2022-07-01
A Study of Fluzoparib（SHR-3162）in BRCA1/2-mutant Relapsed Ovarian Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Completed
NCT04229615 2022-04-25
A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based Chemotherapy
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown
NCT02575651 2019-06-17
A Phase I Study of Fluzoparib in Patient With Advanced Solid Malignancies
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Completed